The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The collaboration will make use of Fluidigm's automated microfluidic systems to accelerate the design of panels for translational and clinical researchers.
The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
The firms will comarket AATI's automated CE systems for quality control analysis of nucleic acids in Illumina's next-generation sequencing workflows.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The companies will market Agena's MassArray Dx system with HeartGenetics' HeartDecode genetic testing software and cardiovascular assays.
Separately, FlowJo and Cytapex Bioinformatics said they have partnered to provide bioinformatics consulting and services for flow cytometry data analysis.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.